Loading quotes...

Forecast

The analysts' average price target is €91.88 (+71.10%). The median is €92.87 (+72.94%).

Buy	17
Hold	7
Sell	2

News Go to news feed

PTC Therapeutics raises forecast – Wells Fargo sees 74% upside potential from Sephience

PTC Therapeutics reports robust sales driven by the drug Sephience and raises its full-year forecast. Wells Fargo reaffirms its buy rating and sets a price target of $112, implying roughly 74% upside. Management says Sephience’s market penetration is proceeding as planned. » More on finanzen.net
PTC Therapeutics: SEPHIENCE drives revenue momentum, cash-flow breakeven targeted for 2026

At the Cantor Healthcare Conference PTC Therapeutics reported a strong SEPHIENCE launch in PKU with over 2,000 therapy-start applications in the U.S. and a global revenue potential of more than $2 billion. The company shows over $2 billion in cash and expects cash-flow breakeven in 2026. Phase‑2 data for votoplam in Huntington’s chorea demonstrated a 52% slowing of disease progression at the higher dose; a Phase‑3 study is already ongoing. PTC is also acquiring ST-920 for Fabry disease (upfront payment $111 million), which is in the BLA stage and could have peak sales potential of more than $750 million. » More on de.investing.com
PTC Therapeutics counts on SUFIANCE as growth driver and targets cash-flow breakeven in 2026

At the Wells Fargo conference PTC Therapeutics outlined its strategy: shifting away from older products toward a broader rare-disease portfolio. SUFIANCE (Pegvaliase) is driving growth, has reached all 103 US centers of excellence and is expected to offer more than $2 billion in revenue potential. Management reports more than $2 billion in cash, disciplined cost reductions and expects cash-flow breakeven in 2026. Meanwhile PTC is expanding its pipeline (including Votoplam, MSH3, Vatiquinon, NLRP3) and is acquiring the gene therapy ST-920 for Fabry disease ($100–110 million) for further diversification. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2013, PTC Therapeutics has already paid €0.0663 in dividends. The last payout was in June 2013.

Financials

In the last quarter, PTC Therapeutics had revenue of €315.89M and net profit of -€45.64M

(EUR)	September 2026	YoY
Revenue	315.89M	75.68%
Gross profit	295M	264.15%
Net profit	-45.64M	436.92%
EBITDA	19.07M	8.47%

Fundamentals

Metric	Value
Market capitalization	€4.47B
Number of shares	83.46M
52-week high/low	€81.14 - €52.51
Dividends	No
Beta	0.55
P/E ratio	-45.78
PEG ratio	0.65
P/B ratio	-26.18
P/S ratio	4.33

Company profile

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.